Hybrigenics SA (ALHYG):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Hybrigenics SA (ALHYG) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10162
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:26
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:フランス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Hybrigenics SA (Hybrigenics) is a biopharmaceutical company that develops new targets and therapies against proliferative and non-cancerous diseases. Its lead product candidate Inecalcitol, is a vitamin D receptor agonist being assessed for various cancer indications including prostate cancer, chronic lymphocytic leukaemia and moderate to severe psoriasis. The company is also investigating the action of deubiquitinating enzymes (DUB) in the recycling of onco-proteins and the utility of proprietary patented DUB inhibitors against various cancer indications. Hybrigenics’ employs its expertise in DUBs to discover and develop new treatments. It also offers specialized scientific services for validating and inhibiting protein interactions in animal, plant or microbiological cells. Hybrigenics is headquartered in Paris, France.

Hybrigenics SA (ALHYG) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Hybrigenics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Hybrigenics SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Hybrigenics SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Hybrigenics SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Hybrigenics SA, Medical Devices Deals, 2012 to YTD 2018 9
Hybrigenics SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Hybrigenics SA, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Hybrigenics Acquires Genomic Division Of Imaxio 11
Equity Offering 12
Hybrigenics Raises USD7.8 Million in Rights Offering of Shares 12
Hybrigenics Raises USD7.1 Million in Public Offering 13
Hybrigenics Raises USD2.7 Million in Private Placement 14
Hybrigenics to Raise USD7.6 Million in Rights Offering of Shares 15
Hybrigenics Raises USD6 Million in Private Placement of Shares 16
Hybrigenics Completes Private Placement Of Shares For US$8.4 Million 17
Hybrigenics Completes Private Placement Of Shares For US$4.1 Million 18
Hybrigenics Completes Second Tranche Private Placement Of Shares For US$1.9 Million 19
Hybrigenics SA – Key Competitors 20
Hybrigenics SA – Key Employees 21
Hybrigenics SA – Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Recent Developments 23
Financial Announcements 23
Apr 26, 2018: Hybrigenics Announces Its Full Year 2017 Results 23
Apr 28, 2017: Hybrigenics fuLL year 2016 resuLts 24
Product News 25
03/26/2018: Hybrigenics broad spectrum inhibitor of Ubiquitin-Specific Proteases shows antiviral activity against human adenoviruses 25
Appendix 26
Methodology 26
About GlobalData 26
Contact Us 26
Disclaimer 26

List of Tables
Hybrigenics SA, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Hybrigenics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Hybrigenics SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Hybrigenics SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Hybrigenics SA, Deals By Therapy Area, 2012 to YTD 2018 8
Hybrigenics SA, Medical Devices Deals, 2012 to YTD 2018 9
Hybrigenics SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Hybrigenics Acquires Genomic Division Of Imaxio 11
Hybrigenics Raises USD7.8 Million in Rights Offering of Shares 12
Hybrigenics Raises USD7.1 Million in Public Offering 13
Hybrigenics Raises USD2.7 Million in Private Placement 14
Hybrigenics to Raise USD7.6 Million in Rights Offering of Shares 15
Hybrigenics Raises USD6 Million in Private Placement of Shares 16
Hybrigenics Completes Private Placement Of Shares For US$8.4 Million 17
Hybrigenics Completes Private Placement Of Shares For US$4.1 Million 18
Hybrigenics Completes Second Tranche Private Placement Of Shares For US$1.9 Million 19
Hybrigenics SA, Key Competitors 20
Hybrigenics SA, Key Employees 21
Hybrigenics SA, Subsidiaries 22

List of Figures
Hybrigenics SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Hybrigenics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Hybrigenics SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Hybrigenics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Hybrigenics SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Hybrigenics SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Hybrigenics SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Hybrigenics SA, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Hybrigenics SA (ALHYG):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Glycotope GmbH-製薬・医療分野:企業M&A・提携分析
    Summary Glycotope GmbH (Glycotope) is a biopharmaceutical company that develops immuno-oncology products for the treatment of various types of cancer. The company’s expression platform offers proprietary technologies such as Glycobody (GET) and GlycoExpress(GEX) that allows the glycosylation of anti …
  • ContourGlobal plc (GLO):企業の財務・戦略的SWOT分析
    ContourGlobal plc (GLO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Protagonist Therapeutics Inc (PTGX):製薬・医療:M&Aディール及び事業提携情報
    Summary Protagonist Therapeutics Inc (Protagonist) is a clinical-stage biopharmaceutical company that discovers and develops orally stable peptides as targeted therapies. The company through its proprietary technology platform develops structurally novel oral or injectable peptides for protein-prote …
  • Amedica Corp (AMDA):製品パイプライン分析
    Summary Amedica Corp (Amedica) is a biomaterial company. It develops, manufactures and markets medical-grade silicon nitride ceramics for spinal and arthroplasty applications. The company offers interbody fusion devices, pedicle screw systems, facet fixation systems and others. Amedica also offers n …
  • Fugro NV (FUR):企業の財務・戦略的SWOT分析
    Fugro NV (FUR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • Tribune Media Co:企業の戦略的SWOT分析
    Tribune Media Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Rice Energy Inc.:企業のM&A・事業提携・投資動向
    Rice Energy Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Rice Energy Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), dives …
  • Mustek Ltd (MST):企業の財務・戦略的SWOT分析
    Mustek Ltd (MST) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • De Lage Landen International B.V.:企業の戦略・SWOT・財務情報
    De Lage Landen International B.V. - Strategy, SWOT and Corporate Finance Report Summary De Lage Landen International B.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Matica Technologies AG:企業の戦略的SWOT分析
    Matica Technologies AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Coca-Cola HBC-Srbija d.o.o.:企業の戦略・SWOT・財務情報
    Coca-Cola HBC-Srbija d.o.o. - Strategy, SWOT and Corporate Finance Report Summary Coca-Cola HBC-Srbija d.o.o. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • BRS Aerospace:企業の戦略・SWOT・財務情報
    BRS Aerospace - Strategy, SWOT and Corporate Finance Report Summary BRS Aerospace - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Vstecs Holdings Ltd:企業の戦略・SWOT・財務分析
    Vstecs Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary Vstecs Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Sykes Enterprises Inc (SYKE):企業の財務・戦略的SWOT分析
    Sykes Enterprises Inc (SYKE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Majesco:企業の戦略・SWOT・財務分析
    Majesco - Strategy, SWOT and Corporate Finance Report Summary Majesco - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • Phagelux Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Phagelux Inc (Phagelux) is an anti-infectives company that provides antibacterial products and solutions. The company uses phage lysis enzymes and biological agents for the treatment of antibiotic resistant bacteria and related diseases in human beings and crops. Its product portfolio includ …
  • The New Zealand Refining Co Ltd (NZR):企業の財務・戦略的SWOT分析
    The New Zealand Refining Co Ltd (NZR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • Rural Bank Limited:企業の戦略・SWOT・財務分析
    Rural Bank Limited - Strategy, SWOT and Corporate Finance Report Summary Rural Bank Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Cara Therapeutics Inc (CARA):医療機器:M&Aディール及び事業提携情報
    Summary Cara Therapeutics Inc (Cara Therapeutics) is a biotechnology company that develops and commercializes chemical entities for acutepain, chronic pain and pruritus. The company offers kappa opioid receptor agonists in the therapeutic areas of acute pain, chronic pain, neuropathic pain and pruri …
  • OAO Gazprom:企業の戦略・SWOT・財務情報
    OAO Gazprom - Strategy, SWOT and Corporate Finance Report Summary OAO Gazprom - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆